Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action

scientific article

Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/CBIC.201300335
P698PubMed publication ID24115455

P50authorFrans A.A. MulderQ58870548
P2093author name stringJakob T Nielsen
Jan K Jensen
Knud J Jensen
Mingdong Huang
Peter A Andreasen
Longguang Jiang
Niels Chr Nielsen
Anni Christensen
Berit Paaske
Renée Roodbeen
P2860cites workTALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shiftsQ24651272
Processing of X-ray diffraction data collected in oscillation modeQ26778468
Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1Q27647131
The binding mechanism of a peptidic cyclic serine protease inhibitorQ27671270
Bicyclic peptide inhibitor reveals large contact interface with a protease targetQ27677040
Bicyclic peptide ligands pulled out of cysteine-rich peptide librariesQ27684366
Coot: model-building tools for molecular graphicsQ27860505
The CCPN data model for NMR spectroscopy: development of a software pipelineQ27860601
Thrombin and vascular inflammationQ28246124
Random coil chemical shifts in acidic 8 M urea: implementation of random coil shift data in NMRViewQ30619296
Selection of a cyclic nonapeptide inhibitor to alpha-chymotrypsin using a phage display peptide libraryQ32049631
A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibitionQ33222784
Novel peptide inhibitors of human kallikrein 2.Q33235991
Phage-encoded combinatorial chemical libraries based on bicyclic peptidesQ33456683
Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogsQ33947706
The plasminogen activation system in tumor growth, invasion, and metastasisQ34008816
Strategies for the inhibition of serine proteasesQ34256075
A simple method to predict protein flexibility using secondary chemical shiftsQ34462699
Inhibitors of the protease domain of urokinase-type plasminogen activatorQ34947102
uPA and uPAR in fibrinolysis, immunity and pathologyQ35846404
Identification of novel peptide inhibitors for human trypsins.Q43175517
A software tool for the prediction of Xaa-Pro peptide bond conformations in proteins based on 13C chemical shift statisticsQ44258185
Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteasesQ47316404
The CCPN project: an interim report on a data model for the NMR communityQ47616220
Random coil chemical shift for intrinsically disordered proteins: effects of temperature and pH.Q53079294
P433issue16
P304page(s)2179-2188
P577publication date2013-10-02
P1433published inChemBioChemQ634395
P1476titleBicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action
P478volume14

Reverse relations

cites work (P2860)
Q34784373A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility
Q36394825Bicyclic Peptides as Next-Generation Therapeutics.
Q30367509Constraining cyclic peptides to mimic protein structure motifs.
Q35231270Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders
Q47098588Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors

Search more.